Quintiles lays off staffers in shift to emerging markets

The big CRO Quintiles laid off an unspecified number of workers late last week, acknowledging a "slight shift" of clinical trial work toward emerging markets. A company spokesperson declined to say just how many workers were pink slipped, but said it amounted to fewer than the number of open jobs it currently lists (about 350). Altogether Quintiles has about 20,000 workers in 60 countries, with 1,400 employed at its headquarters in Research Triangle Park. Story

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.